Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis

Summary

Decreased plasma ADAMTS13 activity (ADAMTS13:AC) results in the accumulation of unusually large von Willebrand factor multimer (UL-VWFM) and the formation of platelet thrombi. It remains controversial whether or not plasma ADAMTS13:AC decreases in patients with liver cirrhosis (LC), and its relationship to clinical features has not been fully investigated. We measured ADAMTS13:AC and its related parameters in plasma in 33 patients with chronic hepatitis (CH) and in 109 patients with LC. ADAMTS13:AC decreased with increasing severity of liver disease (controls means 100%, CH 87%, Child A-LC 79%, Child B-LC 63%, and Child C-LC 31%), and showed severe deficiency (<3% of controls) in five end-stage LC. Activities measured by act-ELISA strongly correlated with those determined by the VWFM assay and ADAMTS13 antigen. Multivariate analysis showed Child-Pugh score and spleen volume independent factors contributing to ADAMTS13:AC. VWFM patterns were normal in 53% of cases, degraded in 31%, and unusually large in 16%. Patients with unusually large VWFM had the lowest ADAMTS13:AC as well as the highest Child-Pugh score, serum creatinine and blood ammonia levels. Plasma inhibitor against ADAMTS13 detected in 83% of patients with severe to moderate ADAMTS13:AC deficiency mostly showed marginal zone between 0.5 and 1.0 BU/ml. The IgG-type autoantibodies specific to plasma derived-ADAMTS13 was detected by Western blot in only five end-stage LC with severe ADAMTS13:AC deficiency. In conclusion, both plasma ADAMTS13 activity and antigen levels decreased with increasing severity of cirrhosis. An imbalance between the decreased ADAMTS13:AC and its increased substrate may reflect the predisposing state for platelet thrombi formation in patients with advanced LC.

Keywords

ADAMTSI3 activity - liver cirrhosis - von Willebrand factor - thrombocytopenia - inhibitor

^* These authors contributed equally to this study.

• References

• 1 Levy GG. et al. Mutations in a member of the ADAMTS13 gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
• 2 Zheng X. et al. Structure of von Willebrand factorcleaving protease (ADAMTS 13), metalloproteinase involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41089-41163.
• 3 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-599.
• 4 Kokame K. et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002; 99: 11902-11907.
• 5 Furlan M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
• 6 Tsai H-M. et al. Antibody to von Willebrand factorcleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
• 7 Moschowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Sac 1924; 24: 21-24.
• 8 Uemura M. et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-924.
• 9 Ferro D. et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23: 1377-1383.
• 10 Albornoz L. et al. Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol 1999; 30: 451-455.
• 11 Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. J Clin Invest 1966; 45: 645-657.
• 12 Peck-Radosavljevic M. et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95: 795-801.
• 13 Schoffski P. et al. Thrombopoietin serum levels are elevated in patients hepatitis B/C infection compared to other causes of chronic liver diseases. Liver 2002; 22: 114-120.
• 14 Amitrano L. et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736-741.
• 15 Wanless IR. et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-1247.
• 16 Oka K. et al. Intravascular coagulation in autopsy cases with liver diseases. Thromb Haemost 1979; 42: 564-570.
• 17 Mannucci PM. et al. Changes in health and disease of the metalloproteinase that cleaves von Willebrand factor. Blood 2001; 98: 2730-2735.
• 18 Park YD. et al. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant 2002; 29: 789-794.
• 19 Uemura M. et al. Decreased Activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2005; 29: 264S-271S.
• 20 Ko S. et al. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. Liver Transpl 2006; 12: 859-869.
• 21 Yagita M. et al. Development of ADAMTS-13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol 2005; 42: 420-421.
• 22 Lisman T. et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.
• 23 Feys HB. et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 534-540.
• 24 Furlan M. et al. Deficiency activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-3103.
• 25 Studt JD. et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105: 542-544.
• 26 Kokame K. et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
• 27 Eckmann CM. et al. Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS-13 activity measurement by FRETSVWF73 assay. J Thromb Haemost 2007; 5: 1330-1331.
• 28 Kato S. et al. Novel monoclonal antibody-based enzyme immunoassay for determinig plasma levels of ADAMTS13 activity. Transfusion 2006; 46: 1444-1452.
• 29 Pugh RNH. et al. Transection of the oesophagus for bleeding oesphageal varices. Br J Surg 1973; 60: 646-649.
• 30 Henderson JM. et al. Measurement of liver and spleen volume by computed tomography. Radiology 1981; 141: 525-527.
• 31 Arroyo V. et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International ascites club. Hepatology 1996; 23: 164-176.
• 32 Kudo M. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-1405.
• 33 Mori Y. et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002; 42: 572-580.
• 34 Yagi H. et al. Plasma Levels of ADAMTS13 antigen determined with an enzyme immunoassay using a neutralizing monoclonal antibody parallel ADAMTS13 activity levels. Int J Hematol 2007; 85: 403-407.
• 35 Ishizashi H. et al. Quantitative Western blot analysis of plasma ADAMTS13 antigen in patients with Upshaw-Schulman syndrome. Thromb Res 2007; 120: 381-386.
• 36 Macfarlane DE. et al. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-308.
• 37 Warren CM. et al. Vertical agarose gel electrophoresis and electroblotting of high-molecular-weight proteins. Electrophoresis 2003; 24: 1695-1702.
• 38 Kasper CK. et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872.
• 39 Hiura H. et al. Immuno-purification of plasma ADAMTS13 and its physico-chemical characterization. International Society on Thrombosis and Haemostasis Congress. Geneva: 2007: P-M-295.
• 40 Liu F. et al. Alteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosus. Thromb Haemost 2006; 95: 749-750.
• 41 Rieger M. et al. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost 2006; 95: 212-220.
• 42 Oleksowicz L. et al. Deficiency of von Willebrand’s factor-cleaving protease in patients with disseminated malignancies. Cancer Res 1999; 59: 2244-2250.
• 43 Schorer AE. et al. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells. Brit J Haematol 1987; 67: 193-197.
• 44 Tornai I. et al. Endothelium releases more von Willebrand factor and tissue-type plasmionogen activator upon venous occlusion in patients with liver cirrhosis than in normals. Haemostasis 1993; 23: 58-64.
• 45 Matsumoto M. et al. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004; 41: 68-74.
• 46 Ikeda K. et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
• 47 Kume Y. et al. Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats. FEBS Letters 2007; 581: 1631-1634.
• 48 Luken BM. et al. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2005; 93: 267-274.
• 49 Tsai HM. et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 95: 886-892.
• 50 Lenzi M. et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut. 1999; 45: 328-329.
• 51 Hsieh MY. et al. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. J Clin Pathol 2008; 61: 333-337.
• 52 Clifford BD. et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 613-619.
• 53 Bernardo A. et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104: 100-106.
• 54 Reiter RA. et al. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 2005; 93: 554-558.
• 55 Ono T. et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 528-534.